Abnormal Uterine Bleeding

  • Rohan R. Chodankar
  • Hilary O. D. CritchleyEmail author
Living reference work entry
Part of the Endocrinology book series (ENDOCR)


Abnormal uterine bleeding (AUB) is a chronic debilitating condition affecting women worldwide with a significant negative impact on their quality of life. Management choices are determined in partnership with an individual woman’s need for uterine and fertility preservation. Although a diverse range of medical and surgical treatment choices are available, a tailored and phenotype-dependent approach to management still remains lacking. AUB, therefore, represents an area of unmet clinical need where future research is needed to optimize information underpinning management choices for women.


Abnormal uterine bleeding (AUB) Heavy menstrual bleeding (HMB) PALM-COEIN Hysterectomy Fibroids Leiomyomas Menstrual cycle Menstruation 


Conflict of Interest

Rohan Chodankar is supported as a Clinical Research Fellow by Bayer AG and has no other conflict of interest. HODC has clinical research support for laboratory consumables and staff from Bayer AG and provides consultancy advice (but with no personal remuneration) for Bayer AG, PregLem SA, Gedeon Richter, Vifor Pharma UK Ltd, AbbVie Inc., Myovant Sciences GmbH. HODC receives royalties from UpToDate for an article on abnormal uterine bleeding.


  1. Abbott JA. Adenomyosis and abnormal uterine bleeding (AUB-A)-pathogenesis, diagnosis, and management. Best Pract Res Clin Obstet Gynaecol. 2017;40:68–81.PubMedCrossRefGoogle Scholar
  2. Abdel-Aleem H, d’Arcangues C, Vogelsong KM, Gaffield ML, Gulmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev. 2013;7:CD003449.Google Scholar
  3. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–7.PubMedCrossRefGoogle Scholar
  4. Borges LM, Scapinelli A, de Baptista Depes D, Lippi UG, Coelho Lopes RG. Findings in patients with postmenstrual spotting with prior cesarean section. J Minim Invasive Gynecol. 2010;17(3):361–4.PubMedCrossRefGoogle Scholar
  5. Brohl AS, Li L, Andikyan V, Obican SG, Cioffi A, Hao K, et al. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist. 2015;20(4):433–9.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Champaneria R, Abedin P, Daniels J, Balogun M, Khan KS. Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy. Acta Obstet Gynecol Scand. 2010;89(11):1374–84.PubMedCrossRefGoogle Scholar
  7. Chen I, Firth B, Hopkins L, Bougie O, Xie RH, Singh S. Clinical characteristics differentiating uterine sarcoma and fibroids. J Soc Laparoendosc Surg. 2018;22(1):e.2017.00066.CrossRefGoogle Scholar
  8. Chodankar R, Allison J. New horizons in fibroid management. J Curr Obsatet Gynaecol Rep. 2018;7(2):106–15.CrossRefGoogle Scholar
  9. Chodankar R, Critchley HOD. Biomarkers in abnormal uterine bleeding. Biol Reprod. 2018. Scholar
  10. Chodankar R, Critchley HO. Abnormal uterine bleeding (including PALM COEIN classification). Obstet Gynaecol Reprod Med. 2019;29:98.. (in press)CrossRefGoogle Scholar
  11. Chodankar R, Harpur A, Mahmood T. Heavy menstrual bleeding. Obstet Gynaecol Reprod Med. 2018;28(7):196–202.CrossRefGoogle Scholar
  12. Critchley HO, Maybin JA. Molecular and cellular causes of abnormal uterine bleeding of endometrial origin. Semin Reprod Med. 2011;29(5):400–9.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Daniels JP, Middleton LJ, Champaneria R, Khan KS, Cooper K, Mol BW, et al. Second generation endometrial ablation techniques for heavy menstrual bleeding: network meta-analysis. BMJ. 2012;344:e2564.PubMedPubMedCentralCrossRefGoogle Scholar
  14. eMC. Esmya 5 mg tablets (ulipristal acetate) electronic Medicines Compendium (eMC); 2018.
  15. Fergusson RJ, Lethaby A, Shepperd S, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;11:CD000329.Google Scholar
  16. Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007a;22(3):635–43.PubMedCrossRefPubMedCentralGoogle Scholar
  17. Fraser IS, Critchley HO, Munro MG, Broder M. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007b;87(3):466–76.PubMedCrossRefPubMedCentralGoogle Scholar
  18. Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383–90.PubMedCrossRefPubMedCentralGoogle Scholar
  19. FSRH. Clinical guidance: problematic bleeding with hormonal contraception: faculty of sexual & reproductive healthcare (FSRH); 2015.
  20. Garcia L, Isaacson K. Adenomyosis: review of the literature. J Minim Invasive Gynecol. 2011;18(4):428–37.PubMedCrossRefGoogle Scholar
  21. Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contraception. 2007;75(6 Suppl):S93–8.PubMedCrossRefGoogle Scholar
  22. Hoffman MK, Meilstrup JW, Shackelford DP, Kaminski PF. Arteriovenous malformations of the uterus: an uncommon cause of vaginal bleeding. Obstet Gynecol Surv. 1997;52(12):736–40.PubMedCrossRefGoogle Scholar
  23. Jacobson FJ, Enzer N. Uterine myomas and the endometrium; study of the mechanism of bleeding. Obstet Gynecol. 1956;7(2):206–10.PubMedGoogle Scholar
  24. Kouides PA, Conard J, Peyvandi F, Lukes A, Kadir R. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertil Steril. 2005;84(5):1345–51.PubMedCrossRefGoogle Scholar
  25. Lieng M, Istre O, Sandvik L, Qvigstad E. Prevalence, 1-year regression rate, and clinical significance of asymptomatic endometrial polyps: cross-sectional study. J Minim Invasive Gynecol. 2009;16(4):465–71.PubMedCrossRefGoogle Scholar
  26. Lieng M, Istre O, Qvigstad E. Treatment of endometrial polyps: a systematic review. Acta Obstet Gynecol Scand. 2010;89(8):992–1002.PubMedCrossRefGoogle Scholar
  27. Liu X, Ding D, Ren Y, Guo SW. Transvaginal Elastosonography as an Imaging Technique for Diagnosing Adenomyosis. Reprod Sci. 2018;25(4):498–514.PubMedCrossRefGoogle Scholar
  28. Mansour D. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. J Fam Plann Reprod Health Care. 2012;38(3):148–9.PubMedCrossRefGoogle Scholar
  29. Maybin JA, Critchley HO. Menstrual physiology: implications for endometrial pathology and beyond. Hum Reprod Update. 2015;21(6):748–61.PubMedPubMedCentralCrossRefGoogle Scholar
  30. MHRA. Esmya (ulipristil acetate) for symptoms of uterine fibroids: restrictions to use and requirement to check liver function before, during and after treatment: medicines and healthcare products regulatory agency (MHRA); 2018.
  31. Morris H. Surgical pathology of the lower uterine segment caesarean section scar: is the scar a source of clinical symptoms? Int J Gynecol Pathol. 1995;14(1):16–20.PubMedCrossRefGoogle Scholar
  32. Multinu F, Casarin J, Tortorella L, Huang Y, Weaver A, Angioni S, et al. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study. Am J Obstet Gynecol. 2019;220(2):179 e1–e10.CrossRefGoogle Scholar
  33. Munro MG, Critchley HO, Broder MS, Fraser IS (2011), FIGO classification system (PALM–COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3–13. Scholar
  34. Munro MG, Critchley HOD, Fraser IS, Committee FMD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408.PubMedCrossRefPubMedCentralGoogle Scholar
  35. NICE. Clinical Guideline 44; Heavy menstrual bleeding: National Institute for Health and Clinical Excellence (NICE); 2007.
  36. NICE. NG88: heavy menstrual bleeding: assessment and management: National Institute for Health and Clinical Excellence (NICE); 2018.
  37. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994–1997 FIGO committee on gynecologic oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999;65(3):243–9.PubMedCrossRefPubMedCentralGoogle Scholar
  38. RCOG. National heavy menstrual bleeding audit – final report. London: RCOG; 2014a.
  39. RCOG. Advice for Heavy Menstrual Bleeding (HMB) Services and Commissioners; 2014b.
  40. Reavey JJ, Maybin JA, Critchley HO. Physiology of menstruation. In: Kadir RA, James PD, Lee CA, editors. Inherited bleeding disorders in women. 2nd ed. Hoboken: Wiley Blackwell; 2018. p. 29–44.CrossRefGoogle Scholar
  41. Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol. 2018;151(3):562–72.PubMedCrossRefGoogle Scholar
  42. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG. 2004;111(7):734–40.PubMedCrossRefGoogle Scholar
  43. Sizzi O, Manganaro L, Rossetti A, Saldari M, Florio G, Loddo A, et al. Assessing the risk of laparoscopic morcellation of occult uterine sarcomas during hysterectomy and myomectomy: literature review and the ISGE recommendations. Eur J Obstet Gynecol Reprod Biol. 2018;220:30–8.PubMedCrossRefGoogle Scholar
  44. Speroff L, Fritz MA. Clinical gynecologic endocrinology and fertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.Google Scholar
  45. Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293–8.PubMedCrossRefGoogle Scholar
  46. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137(5):1621–7.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Thomas CC, Wingo PA, Dolan MS, Lee NC, Richardson LC. Endometrial cancer risk among younger, overweight women. Obstet Gynecol. 2009;114(1):22–7.PubMedCrossRefGoogle Scholar
  48. Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284–98.PubMedCrossRefGoogle Scholar
  49. Woolcock JG, Critchley HO, Munro MG, Broder MS, Fraser IS. Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertil Steril. 2008;90(6):2269–80.PubMedCrossRefGoogle Scholar
  50. Zalewski K, Misiek M, Gozdz S, Bidzinski M. The new FIGO staging system for ovarian, fallopian tube and primary peritoneal cancer – 2014 update. Oncol Clin Pract. 2015;11(3):129–34.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.MRC Centre for Reproductive Health, The Queen’s Medical Research InstituteThe University of EdinburghEdinburghUK

Personalised recommendations